{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:21:31Z","timestamp":1790706091712,"version":"4.1.0"},"update-to":[{"DOI":"10.12688\/f1000research.168760.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000}}],"reference-count":28,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns7:p>Background Diffuse large B-cell lymphoma (DLBCL) exhibits heterogeneous clinical outcomes, including variations in event-free survival (EFS). Tumor microenvironment (TME) components, particularly absolute monocyte count (AMC), tumor-associated macrophages (TAMs), and tumor-infiltrating lymphocytes (TILs) have been implicated in prognosis, although findings remain inconsistent. This study evaluates the prognostic value of AMC, TAMs (CD163), and TILs (CD8) on two-year EFS in DLBCL patients treated with R-CHOP. Methods A retrospective cohort study of 108 DLBCL patients treated from January 2014 to March 2021 was conducted. AMC was obtained from peripheral blood, while CD163 and CD8 expressions were analyzed via immunohistochemistry. Associations with two-year EFS were assessed using hazard ratios (HR), and correlations between AMC and tissue immune markers were evaluated. Results High AMC and CD163 expression were significantly associated with poorer two-year EFS (HR = 9.82 and 8.57; both p &lt; 0.001), whereas elevated CD8 expression predicted better outcomes (HR = 0.13; p &lt; 0.001). AMC positively correlated with CD163 (r = 0.577; p &lt; 0.001) and negatively with CD8 (r = \u20130.599; p &lt; 0.001). Conclusion AMC and CD163 are negative prognostic markers, while CD8 is protective. AMC may reflect the immune profile of the TME and serve as a practical prognostic biomarker in DLBCL.<\/ns7:p>","DOI":"10.12688\/f1000research.168760.2","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:29:10Z","timestamp":1773307750000},"page":"814","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic Role of Absolute Monocyte Count, CD163\u207a Macrophages, and CD8\u207a Lymphocytes in Diffuse Large B-Cell Lymphoma Treated with R-CHOP"],"prefix":"10.12688","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8366-6364","authenticated-orcid":false,"given":"Faisal","family":"Syarifuddin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4961-1737","authenticated-orcid":false,"given":"Anna Mira","family":"Lubis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes Stephanie","family":"Harahap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1393-9669","authenticated-orcid":false,"given":"Hamzah","family":"Shatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wulyo","family":"Rajabto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imam","family":"Subekti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudy","family":"Hidayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukamto","family":"Koesnoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"842-858","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma.","volume":"384","author":"L Sehn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2041-2048","DOI":"10.1182\/blood.2019002729","article-title":"International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI.","volume":"135","author":"A Ruppert","year":"2020","journal-title":"Blood."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"947-952","DOI":"10.1089\/dna.2018.4374","article-title":"Biology of tumor associated macrophages in diffuse large B cell lymphoma.","volume":"37","author":"W Huang","year":"2018","journal-title":"DNA Cell Biol."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"125-130","DOI":"10.3324\/haematol.2013.088161","article-title":"Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era.","volume":"99","author":"T Tadmor","year":"2014","journal-title":"Haematologica."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2961-2977","DOI":"10.2147\/CMAR.S245928","article-title":"The neutrophil to lymphocyte and lymphocyte to monocyte ratios as new prognostic factors in hematological malignancies\u2014a narrative review.","volume":"12","author":"P Stefaniuk","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"888-897","DOI":"10.1111\/bjh.16263","article-title":"New prognosis score including absolute lymphocyte\/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO).","volume":"188","author":"L Bento","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1062-1067","DOI":"10.1002\/ajh.23566","article-title":"The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.","volume":"88","author":"A Rambaldi","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"127-135","DOI":"10.3960\/jslrt.22027","article-title":"Lymphoma microenvironment in DLBCL and PTCL-NOS: the key to uncovering heterogeneity and the potential for stratification.","volume":"62","author":"K Miyawaki","year":"2022","journal-title":"J. Clin. Exp. Hematop."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"493-497","DOI":"10.3960\/jslrt.22027","article-title":"Correlation between circulating blood and microenvironment T lymphocytes in diffuse large B-cell lymphomas.","volume":"75","author":"F Laddaga","year":"2022","journal-title":"J. Clin. Pathol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"109779","DOI":"10.1016\/j.cbi.2021.109779","article-title":"Diffuse large B-cell lymphoma-derived exosomes push macrophage polarization toward M2 phenotype via GP130\/STAT3 signaling pathway.","volume":"352","author":"H Ling","year":"2022","journal-title":"Chem. Biol. Interact."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"19556-19565","DOI":"10.18632\/oncotarget.14700","article-title":"Peripheral blood lymphocyte to monocyte ratio recovery from low levels at diagnosis after completion of first line therapy predicts good clinical outcomes in patients with diffuse large B-cell lymphoma.","volume":"8","author":"S Zhou","year":"2017","journal-title":"Oncotarget."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"694-698","DOI":"10.1016\/j.leukres.2014.03.013","article-title":"Low lymphocyte-to-monocyte ratio predicts unfavorable prognosis in non-germinal center type diffuse large B-cell lymphoma.","volume":"38","author":"X Wei","year":"2014","journal-title":"Leuk. Res."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1066-1073","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.","volume":"32","author":"M Maurer","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2403-2418","DOI":"10.1080\/10428194.2017.1287366","article-title":"Does cell-of-origin or MYC, BCL2 or BCL6 translocation status provide prognostic information beyond the International Prognostic Index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review.","volume":"58","author":"M Schmidt-Hansen","year":"2017","journal-title":"Leuk. Lymphoma."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"15-18","DOI":"10.1016\/j.clml.2012.07.002","article-title":"The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP.","volume":"13","author":"N Batty","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"323-328","DOI":"10.1016\/j.leukres.2013.12.011","article-title":"The lower peripheral blood lymphocyte\/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.","volume":"38","author":"Y Li","year":"2014","journal-title":"Leuk. Res."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"529-532","DOI":"10.1111\/j.1440-1827.2008.02269.x","article-title":"Expression of CD68+ tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis.","volume":"58","author":"S Hasselblom","year":"2008","journal-title":"Pathol. Int."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"229-239","DOI":"10.1007\/s00428-013-1519-2","article-title":"The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone.","volume":"464","author":"H Rajnai","year":"2014","journal-title":"Virchows Arch."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"717-734","DOI":"10.1038\/nrclinonc.2017.101","article-title":"The immune contexture in cancer prognosis and treatment.","volume":"14","author":"W Fridman","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1186\/s12885-019-6210-y","article-title":"Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count.","volume":"19","author":"Y Li","year":"2019","journal-title":"BMC Cancer."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1553-1560","DOI":"10.4067\/S0034-98872019001201553","article-title":"Absolute monocyte count as a prognostic parameter in diffuse large B cell lymphoma.","volume":"147","author":"V Irigo\u00edn","year":"2019","journal-title":"Rev. Med. Chile."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"851-856","DOI":"10.3892\/ol.2014.2755","article-title":"Prognostic effect of peripheral blood cell counts in advanced diffuse large B-cell lymphoma treated with R-CHOP-like chemotherapy: a single institution analysis.","volume":"9","author":"T Yamauchi","year":"2015","journal-title":"Oncol. Lett."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2913-2924","DOI":"10.1158\/1078-0432.CCR-15-2238","article-title":"CD8+ T-cell infiltration and expression of PD-1 and PD-L1 in DLBCL predicts survival and response to chemotherapy.","volume":"22","author":"C Keane","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"386-391","DOI":"10.1016\/j.leukres.2012.12.009","article-title":"Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOP.","volume":"37","author":"J Castillo","year":"2013","journal-title":"Leuk. Res."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"BSR20191162","DOI":"10.1042\/BSR20191162","article-title":"Genetic polymorphism and transcriptional regulation of CREBBP gene in patient with diffuse large B-cell lymphoma.","volume":"39","author":"H Zhao","year":"2019","journal-title":"Biosci. Rep."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"4184-4190","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.","volume":"28","author":"C Gisselbrecht","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1186\/s12885-018-4850-6","article-title":"The prognostic and predictive value of tumor-infiltrating lymphocytes and hematologic parameters in patients with breast cancer.","volume":"18","author":"K Lee","year":"2018","journal-title":"BMC Cancer."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.29818244.v1","author":"F Syarifuddin","year":"2025","journal-title":"figshare."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/14-814\/v2\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/14-814\/v2\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/14-814\/v2\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T06:39:07Z","timestamp":1774852747000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/14-814\/v2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":28,"URL":"https:\/\/doi.org\/10.12688\/f1000research.168760.2","relation":{"has-version":[{"id-type":"doi","id":"10.12688\/f1000research.168760.1","asserted-by":"subject"}],"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.196782.r467144","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.196782.r467762","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.196782.r467144","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/14-814\/v2#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.185964.r427565, Jenifer Vaughan, University of the Witwatersrand J, Johannesburg, Gauteng, 12 Nov 2025, version 1, 1 approved, 1 approved with reservations","URL":"https:\/\/f1000research.com\/articles\/14-814\/v1#referee-response-427565","order":0,"name":"referee-response-427565","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"<b>Faisal Syarifuddin<\/b>; \n<i>Posted: 21 Feb 2026<\/i>; We sincerely thank the reviewer for the constructive feedback, which has significantly improved the clarity and methodological transparency of our manuscript. The revisions are summarized below:  The title has been revised to explicitly specify CD163\u207a macrophages and CD8\u207a lymphocytes to accurately reflect the immune subsets evaluated. Corresponding changes have been made in the Abstract for consistency. The Ethics section has been clarified to state that written informed consent was obtained from surviving patients whenever feasible, while consent for deceased patients was waived in accordance with ethics committee approval. The immunohistochemical quantification method has been revised to clarify that CD8 expression was measured as the percentage of CD8-positive lymphocytes among total nucleated cells within each high-power field using ImageJ&reg; software, correcting the previous ambiguity. The typographical error regarding the number of event-free patients has been corrected (46 patients). The unit for CD163 expression has been standardized as cells\/HPF throughout the manuscript. Units for AMC (cells\/&micro;L), CD163 (cells\/HPF), and CD8 (%) have been added in Table 1 to improve clarity. The figure legend has been corrected to accurately reflect CD8 expression levels. Extranodal involvement and the median event-free survival time (13 months) are now explicitly reported in the Results section to avoid introducing new findings in the Discussion. The rationale for selecting two-year event-free survival (EFS24) as the primary endpoint has been clarified, emphasizing its established relevance as a clinically meaningful surrogate marker in DLBCL.  We greatly appreciate the reviewer\u2019s thoughtful comments, which have strengthened the overall quality and transparency of the manuscript.","URL":"https:\/\/f1000research.com\/articles\/14-814\/v2#referee-comment-15504","order":1,"name":"referee-comment-15504","label":"Referee Comment","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.196782.r467144, Rafael Pichardo-Rodriguez, Instituto de Investigaciones en Ciencias Biom\u00e9dicas (INICIB), Universidad Ricardo Palma, Lima, 30 Mar 2026, version 2, indexed","URL":"https:\/\/f1000research.com\/articles\/14-814\/v2#referee-response-467144","order":2,"name":"referee-response-467144","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}